2024.11.01 | views:818
DXVX Develops Groundbreaking Technology to Overcome mRNA Vaccine Storage Limitations Verifies Possibility of Room-Temperature Storage for Over 10 Years Through Preliminary Research
2024.11.01 | views:440
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
2024.10.30 | views:451
Dx&Vx, ‘상온 초장기 비축 mRNA백신소재 및 대량생산 공정기술 개발’ 국책과제 선정
2024.10.30 | views:683
Dx&Vx, 'Room temperature ultra-long-term stockpiling mRNA vaccine material and mass production process technology development' selected as national projec
2024.10.30 | views:215
DXVX, ‘상온 초장기 비축 mRNA 백신 소재 및 대량 생산 공정 기술 개발’ 국책과제 선정
2024.10.30 | views:144
Dx&Vx, '한국형 ARPA-H' 선정…mRNA 백신 검증·사업화 담당
2024.10.28 | views:411
디엑스앤브이엑스, 영국 OVM 항암백신 도입 실사 완료
2024.10.28 | views:743
디엑스앤브이엑스,'Medical Japan 2024 Tokyo'서 헬스케어 제품 소개
2024.10.28 | views:143
Dx&Vx, Medical Japan 2024 Tokyo 참석… 글로벌 사업 확장 지속
  1.   
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8
  7. 9
  8. 10
  9.